Last reviewed · How we verify
NCT02991794: PROSTEVIS
Prostatectomies Using Einstein Vision® 3D
trial testing EinsteinVision 3D visualization system in Prostate Carcinoma in 156 participants. Completed in 6 November 2020.
31 December 2019
Quick facts
| Lead sponsor | Aesculap AG |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 156 |
| Start date | 19 May 2017 |
| Primary completion | 31 December 2019 |
| Estimated completion | 6 November 2020 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- EinsteinVision 3D visualization system
Conditions studied
- Prostate Carcinoma — all drugs for Prostate Carcinoma →
Sponsor
Aesculap AG — full company profile →
Who can join
18 and older, male only, with Prostate Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is collecting clinical data on the learning curve of different surgeons using the EinsteinVision® 3D visualization system in laparoscopic radical prostatectomies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02991794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Carcinoma
Currently open trials in the same condition.
- NCT07218718 — Oral Cryotherapy to Decrease Taste Changes in Prostate Cancer Patients Receiving Taxane Chemotherapy · NA · recruiting
- NCT07202247 — Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabol · Phase 2 · recruiting
- NCT06957691 — Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Pro · Phase 2 · recruiting
- NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
Other Aesculap AG trials
Trials by the same sponsor.
- NCT05441618 — Post Market Clinical Follow-Up Study on the Performance and Safety of Lyoplant® · completed
- NCT05944081 — Postmarket Clinical Follow-Up Study on Arcadius XP L® Interbody Fusion Device · withdrawn
- NCT06298500 — Clinical Performance of HISTOACRYL® LAPFIX - CANNULA for Laparoscopic Inguinal Hernia Repair · completed
- NCT06055946 — Symmcora® Long-term Bidirectional Barbed Suture for Anastomosis in Patients Undergoing Robot Assisted Radical Prostatect · completed
- NCT05182320 — Study Measuring the Effects of Patient Data for Total Hip and Total Knee Arthroplasty Patients Using an APP Based Sensor · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02991794 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aesculap AG
- Last refreshed: 13 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02991794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing